Therapeutic potential of fluoxetine in neurological disorders

被引：73

作者：

Mostert, Jop P. ^{[1
]}

Koch, Marcus W. ^{[1
]}

Heerings, Marco ^{[1
]}

Heersema, Dorothea J. ^{[1
]}

De Keyser, Jacques ^{[1
]}

机构：

[1] Univ Groningen, Dept Neurol, Univ Med Ctr Groningen, NL-9713 GZ Groningen, Netherlands

来源：

CNS NEUROSCIENCE & THERAPEUTICS | 2008年 / 14卷 / 02期

关键词：

fluoxetine; neurodegeneration; neurological disorders; neuroprotection;

D O I：

10.1111/j.1527-3458.2008.00040.x

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

The selective serotonin reuptake inhibitor (SSRI) fluoxetine, which is registered for a variety of psychiatric disorders, has been found to stimulate the cAMP-responsive element binding protein (CREB), increase the production of brain-derived neurotrophic factor (BNDF) and the neurotrophic peptide S100 beta, enhance glycogenolysis in astrocytes, block voltage-gated calcium and sodium channels, and decrease the conductance of mitochondrial voltage-dependent anion channels (VDACs). These mechanisms of actions suggest that fluoxetine may also have potential for the treatment of a number of neurological disorders. We performed a Pubmed search to review what is known about possible therapeutic effects of fluoxetine in animal models and patients with neurological disorders. Beneficial effects of fluoxetine have been noted in animal models of stroke, multiple sclerosis, and epilepsy. Fluoxetine was reported to improve neurological manifestations in patients with Alzheimer's disease, stroke, Huntington's disease, multiple sclerosis, traumatic brain injury, and epilepsy. Clinical studies so far were small and often poorly designed. Results were inconclusive and contradictory. However, the available preclinical data justify further clinical trials to determine the therapeutic potential of fluoxetine in neurological disorders.

引用

页码：153 / 164

页数：12

共 83 条

[1]

Auchus AP, 1997, J NEUROPSYCH CLIN N, V9, P591

[2] Mitochondria take center stage in aging and neurodegeneration [J].

Beal, MF .

ANNALS OF NEUROLOGY, 2005, 58 (04) :495-505

[3] CLINICAL-PHARMACOLOGY AND PHARMACOKINETICS OF FLUOXETINE - A REVIEW [J].

BERGSTROM, RF ;

LEMBERGER, L ;

FARID, NA ;

WOLEN, RL .

BRITISH JOURNAL OF PSYCHIATRY, 1988, 153 :47-50

[4] Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson's disease and concurrent depression [J].

Boggio, PS ;

Fregni, F ;

Bermpohl, F ;

Mansur, CG ;

Rosa, M ;

Rumi, DO ;

Barbosa, ER ;

Rosa, MO ;

Pascual-Leone, A ;

Rigonatti, SP ;

Marcolin, MA ;

Silva, MTA .

MOVEMENT DISORDERS, 2005, 20 (09) :1178-1184

[5] Glycogen regulation and functional role in mouse white matter [J].

Brown, AM ;

Tekkök, SB ;

Ransom, BR .

JOURNAL OF PHYSIOLOGY-LONDON, 2003, 549 (02) :501-512

[6]

BROWNING WN, 1990, AM J PSYCHIAT, V147, P1089

[7] Early-life fluoxetine exposure reduced functional deficits after hypoxic-ischemia brain injury in rat pups [J].

Chang, Ying-Chao ;

Tzeng, Shun-Fen ;

Yu, Lung ;

Huang, A-Min ;

Lee, Hsueh-Te ;

Huang, Chao-Ching ;

Ho, Chien-Jung .

NEUROBIOLOGY OF DISEASE, 2006, 24 (01) :101-113

[8] FURTHER EVIDENCE THAT FLUOXETINE INTERACTS WITH A 5-HT2C RECEPTOR IN GLIAL-CELLS [J].

CHEN, Y ;

PENG, LA ;

ZHANG, XH ;

STOLZENBURG, JU ;

HERTZ, L .

BRAIN RESEARCH BULLETIN, 1995, 38 (02) :153-159

[9]

CHOI DW, 1995, TRENDS NEUROSCI, V18, P58

[10] Cyclic AMP inhibition of tumor necrosis factor α production induced by amyloidogenic C-terminal peptide of Alzheimer's amyloid precursor protein in macrophages:: Involvement of multiple intracellular pathways and cyclic AMP response element binding protein [J].

Chong, YH ;

Shin, YJ ;

Suh, YH .

MOLECULAR PHARMACOLOGY, 2003, 63 (03) :690-698

← 1 2 3 4 5 6 7 8 9 →